Search: onr:"swepub:oai:lup.lub.lu.se:5aeda821-e0e8-4cf5-86e4-c1ff6e873287" >
Real-world cost-eff...
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
- Article/chapterEnglish2015
Publisher, publication year, extent ...
-
2014-10-21
-
Informa UK Limited,2015
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:5aeda821-e0e8-4cf5-86e4-c1ff6e873287
-
https://lup.lub.lu.se/record/7791118URI
-
https://doi.org/10.3109/10428194.2014.953141DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-239858URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:131560767URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
De två första författarna delar förstaförfattarskapet.
-
Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on patients with CML diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-alpha/stem cell transplant and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and quality of life estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the respective time periods. The incremental cost-effectiveness ratio (ICER) between periods III and II was (sic)52 700 per quality-adjusted life year (QALY) gained. An estimated 80% price reduction of imatinib, related to patent expiry, would reduce this ICER to (sic)22 700. Our data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Lundqvist, Adam
(author)
-
Dickman, PaulKarolinska Institutet
(author)
-
Höglund, MartinUppsala universitet,Hematologi(Swepub:uu)martinhl
(author)
-
Persson, UlfLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics(Swepub:lu)tft-upe
(author)
-
Stenke, LeifKarolinska Institutet
(author)
-
Carlsson, Katarina Steen
(author)
-
Bjorkholm, MagnusKarolinska Institutet
(author)
-
Karolinska InstitutetHematologi
(creator_code:org_t)
Related titles
-
In:Leukemia & Lymphoma: Informa UK Limited56:5, s. 1385-13911042-81941029-2403
Internet link
Find in a library
To the university's database